TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
28.30
+0.08 (0.28%)
Jun 18, 2026, 4:08 PM HKT
Market Cap11.51B
Revenue (ttm)n/a
Net Income-329.35M
EPS-0.85
Shares Out 407.92M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,599,000
Open28.18
Previous Close28.22
Day's Range27.40 - 29.22
52-Week Range20.20 - 679.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 25, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 123
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements